Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10730593 | 0.93 | SMPD1 (0.60) | MTNR1AMTNR1BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10731769 | 0.93 | MTNR1A (0.64) | MTNR1AMTNR1BNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL24505350 | 0.88 | FFAR4 (0.68) | FFAR4MAPTFOLH1SMN1; SMN2RXRA | |
| SCHEMBL3817639 | 0.87 | FFAR4 (0.55) | MTNR1AMTNR1BFFAR4MAPTPOLB | |
| SCHEMBL5273788 | 0.87 | SMN1; SMN2 (0.52) | FFAR4MAPTTHRBFOLH1RAB9A | |
| SCHEMBL10980236 | 0.87 | NPC1 (0.57) | FFAR4MAPTFOLH1NPC1RAB9A | |
| SCHEMBL26851429 | 0.85 | MTNR1A (0.55) | MTNR1AMTNR1BFFAR4MAPTPOLB | |
| SCHEMBL11827307 | 0.85 | FFAR4 (0.64) | MTNR1AMTNR1BFFAR4MAPTPOLB | |
| SCHEMBL6214774 | 0.84 | FOLH1 (0.51) | MTNR1AMTNR1BFFAR4MAPTPOLB | |
| SCHEMBL8072945 | 0.84 | PTGER1 (0.52) | MTNR1AMTNR1BFFAR4MAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217945-A1 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND THEIR USE | ARCADIA MEDICINE, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20240217945-A1 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND THEIR USE | ARCADIA MEDICINE, INC. | 2024-07-04 | — | — | US | disclosed |
| EP-4392402-A1 | SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES | Mind Medicine, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20240115710-A1 | SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES | Mind Medicine, Inc. (US) | 2024-04-11 | — | — | US | disclosed |
| US-11896670-B2 | Synthesis routes to access MDMA prodrugs by using controlled and non-controlled intermediates | Mind Medicine, Inc. (US) | 2024-02-13 | — | — | US | disclosed |
| US-20230382885-A1 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND THEIR USE | ARCADIA MEDICINE, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382885-A1 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND THEIR USE | ARCADIA MEDICINE, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230227420-A1 | PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | EMPATHBIO, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230227420-A1 | PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | EMPATHBIO, INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2023056102-A1 | NOVEL PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | ATAI Life Sciences AG (DE) | 2023-04-06 | — | — | WO | disclosed |
| US-20230066171-A1 | SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES | Mind Medicine, Inc. (US) | 2023-03-02 | — | — | US | disclosed |
| WO-2023028022-A1 | SYNTHESIS ROUTES TO ACCESS MDMA PRODRUGS BY USING CONTROLLED AND NON-CONTROLLED INTERMEDIATES | Mind Medicine, Inc. (US) | 2023-03-02 | — | — | WO | disclosed |
| US-5482971-A | Beta3 -adrenergic agents and their use in pharmaceutical compositions | AMERICAN CYANAMID COMPANY (US) | 1996-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227420-A1 | PRODRUGS OF MDMA, MDA, AND DERIVATIVES THEREOF | COMT, PNMT, ABCB1 | MTNR1A 311/4885MTNR1B 260/4885FFAR4 1004/4885 |
| US-20240217945-A1 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND THEIR USE | HTR1A, PNMT, HTR2C | MTNR1A 357/4885MTNR1B 527/4885FFAR4 2397/4885 |
| US-20230382885-A1 | ENANTIOMERIC ENTACTOGEN COMPOSITIONS AND THEIR USE | HTR1A, PNMT, HTR2C | MTNR1A 357/4885MTNR1B 527/4885FFAR4 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.